The growth of 26 short normal prepubertal children (mean age 8-4, height velocity standard deviation score for chronological age between +0-4 and -0-8) was studied for two years. Sixteen children were treated with somatrem (methionyl growth hormone) during the second year, and the remaining 10 children served as controls. During one year of treatment the height velocity standard deviation score for chronological age increased from the pretreatment mean of -044 (SD 0.33) to +2*20 (1.03). These values represented a change in height velocity from a pretreatment mean of 5-3 cm/year (range 4.6-6.9) to 7-4 cm/year (range 5-7-9-9). In the control group the height velocity standard deviation score was unchanged. Bone age advanced by 0-75 (0-33) years in the treated group compared with 0-70 (0.18) years in the control group. There was a significant increase in the height standard deviation score for bone age (0-63 (0.55)) in the treated group.
Introduction
We have recently shown an asymptomatic relation between the height velocity of short prepubertal children and the amount of growth hormone secreted over 24 hours.' The implication of this relation was, firstly, that children growing poorly and secreting little growth hormone would respond best to growth hormone treatment, a hypothesis well tested and proved by experience with human growth hormone treatment2 3; and, secondly, short children growing with a normal growth velocity would also respond, albeit to a lesser extent.
The second hypothesis has not been tested to any extent owing to limited supplies of human growth hormone. Several groups have reported a beneficial effect of exogenous growth hormone in short "normal" children, but the definition of normality was based predominantly on the biochemical response to pharmacological testing with little account taken of the children's growth rate. 49 If children are not to gain or lose height compared with their peers then they must grow with a 50th centile height velocity.'0 In practice, as children growing along or parallel to the third height centile grow slightly slower and tall children slightly faster than the mean, height velocities that fall continuously between the 25th and 75th centiles are accepted as normal (height velocity standard deviation score +0-8 to -0 8). If height velocity is used to define normality only 12 of the 91 children reported on were normal.'9 The limitations of defining normality by pharmacological testing have been shown by Bercu et al with the identification of children with neurosecretory dysfunction." '2 Further problems with previous studies included short treatment periods, lack of measurement ofchanges in skeletal maturation, and a failure to take into account the safety of treatment in terms of the formation of antibodies and other possible complications, which include hypertension and glucose intolerance. 49 We report the effect of treatment with somatrem (methionyl growth hormone) for one year on the growth of 16 short normal children and compare the results with those in 10 children who served as controls.
criteria before entry into the study and have: (1) a growth velocity standard deviation score between 0 and -0-8 in the first year of the study; (2) skeletal age less than 10 years; (3) 28-2 (9-1) mU/l in the control group). Children in the control group were slightly taller, but height velocities were identical in the two groups. Height velocity standard deviation score for chronological age increased from a pretreatment mean of -0-44 (0 33) to +2-20 (1-03); this rise was significant within the treatment group (p<0001) and compared with the control group (p<0001) (fig 1) . This was reflected in the change in height standard deviation score for chronological age. The advance in bone age was 0 75 (0-33) years in the treatment group and 0 70 (0-18) years in the control group. Thus the improvement in height standard deviation score was not at the expense of an advance in skeletal maturity. This was confirmed by the significant increase in height standard deviation score for bone age in the treated group (p=0 001). All children remained prepubertal throughout the study.
Triceps and subscapular skinfold thickness standard deviation scores for chronological age at the start of treatment were +0-18 (0 56) and -0-46 (0 45), respectively, in the treated group and +0-26 (043) and -0-39 (0 47), respectively, in the control group. There was no significant change in either of the skinfold standard deviation scores after one year of treatment. There was, however, a significant decline in skinfold thickness in the treatment group over the first six months ofobservation and no change in controls.
There was no change in the mean blood pressure during the course of treatment (70-2 (10-7) mm Hg before treatment and 68-2 (7 4) mm Hg at the end of the year). Table I shows the growth variables in the two groups of children and the effect of treatment. The mean ages of the two groups were similar (SD 194) years in the treated group, 7-29 in the control group). Sex ratios were also similar (1 5M:iF), as were the peak growth hormone responses to an insulin tolerance test (27-9 (9 2) mU/l in the treated group,
DOSE OF SOMATREM
The fixed dose regimen used produced a wide range of doses of somatrem when expressed in terms of body surface area (12-2-2-1-0 units/M2 body surface area/week). The initial plot of change in height velocity standard deviation score for chronological age against somatrem dose suggested a curvilinear relation, but a curvilinear plot did not significantly improve the description compared with a linear one (fig 2) . There was a significant linear relation between the change in height velocity standard deviation score for chronological age (or bone age) and dose/m2/week (r=0-68).
Other factors important in predicting response to treatment were investigated in a multiple stepwise regression. The factors making a significant contribution to the prediction were pretreatment height velocity for either chronological age or bone age and dose of growth hormone. The final multiple regression was: change in height velocity standard deviation score for chronological age=-3-5-(1-2xpretreatment height velocity standard deviation score for chronological age)+0 34 (dose/m2/week). The multiple correlation coefficient was 0 80.
ANTIBODY FORMATION AND EFFECTS OF TREATMENT
Seven of the 16 children receiving treatment developed antibodies to growth hormone. The presence of antibody to E coli protein fluctuated during the course of treatment.
The treatment was well tolerated by all patients, and there were no untoward systemic effects. 15-7 (8-9) mU/1 (p=0 003). This rise in the fasting concentration accounted for the change in the area under the insulin curve to glucose as the incremental area was unchanged during the treatment period. There seemed to be a direct association between the change in the fasting insulin concentration over the treatment period and the dose of growth hormone administered, but this did not achieve significance at the 5% level. No significant differences in fasting triglyceride and cholesterol concentrations were observed at six and 12 months compared with the pretreatment values.
Growth factors-All patients had serum insulin like growth factor 1 concentrations within the normal range for age (boys 0 25-4 40 U/ml, girls 0-36-1 -40 U/ml). After a year of treatment serum insulin like growth factor 1 concentration had risen significantly from a pretreatment mean of 0-48 (0-18) U/rnl to 1-11 (0 50) U/ml (p<0-001). There was no correlation between the change in height velocity for chronological age or bone age and the absolute or change in serum insulin like growth factor 1 concentration. There was no correlation between the height velocity/time and serum insulin like growth factor 1 concentration/time curves. The peak serum insulin like growth factor 1 concentration occurred in the second six month period, whereas the peak growth velocity was noted in the first six months, mainly in the first three months.
Thyroid state-Serum thyroxine concentration did not change during the treatment period. Basal serum thyroid stimulating hormone concentrations were also unchanged, as was the response of serum thyroid stimulating hormone to exogenous thyrotrophin releasing hormone.
Biochemical variables-There was no change in plasma urea and electrolyte and serum calcium concentrations, results of liver function tests, and haematological variables. In addition, there was no change in serum cortisol concentrations at 0800 during treatment or in serum testosterone, oestrogen, and adrenal androgen concentrations.
Discussion
Children growing along or parallel to the third height centile grow with a height velocity standard deviation score between 0 and -0-8, and hence the height centiles widen with age. Our studies of physiological growth hormone secretion in short prepubertal children predicted that such children could be made to grow faster by being given exogenous growth hormone.' This hypothesis was tested in this study, and the increase in height standard deviation score for bone age seen was attributable to somatrem as all patients remained prepubertal; there was no change in serum age, which makes the use of fixed dose regimens all the more inappropriate.27-29 In treating short normal children these effects need to be considered and may explain the poor response to treatment of such children in the past.23 Our regimen, given to children with a wide range ofages, enabled us to obtain a wide range of doses and an equally wide range of responses (fig 2) . Serum insulin like growth factor 1 concentrations have been regarded by some as having predictive value in assessing response to growth hormone treatment,4 although it is generally accepted that the correlation is poor7'I-; our findings confirm this last observation. This poor relation probably reflects the fact that insulin like growth factor 1 is predominantly a paracrine hormone, so that serum concentrations need not necessarily reflect important changes in tissue concentrations.3"-33
Administration of human growth hormone has been associated with alterations in thyroid function, reduced thyroxine and triiodothyronine concentrations,-' and blunted thyroid stimulating hormone responses to thyrotrophin releasing hormone.341-Increased somatostatin secretion has been postulated as the mechanism.35 Several ofthe patients reported on, however, had borderline thyroid function; growth hormone treatment may have unmasked hypothyroidism or it may have arisen in the context of an evolving endocrinopathy.36 None of the children in our study developed low serum thyroxine concentrations, nor was the response of serum thyroid stimulating hormone to exogenous thyrotrophin releasing hormone blunted. This last observation is complemented by animal work, which shows that growth hormone autofeedback is mediated by reduced secretion of growth hormone releasing hormone rather than enhanced release of somatostatin.37 Growth hormone also directly feeds back on the pituitary.3'
Acromegaly is characterised by excessive growth hormone secretion, and concern has been expressed that short normal children given growth hormone may develop a similar condition in association with hypertension and diabetes mellitus.4' None of our children developed hypertension or glucose intolerance as measured by oral glucose loading and glycosylated haemoglobin concentrations.
The unchanged glucose tolerance was obtained at the expense ofa rise in fasting insulin concentrations, but the insulin response to glucose loading (indicated by the incremental area under the insulin curve) was unchanged. This suggests that the predominant effect of growth hormone is to produce insulin resistance as previously reported.42 This effect may be interpreted either as an undesirable side effect of treatment, which might lead to carbohydrate intolerance, or as an inevitable consequence of treatment and a necessity for the full expression of growth hormone anabolic activity: evidence for the last suggestion comes from animal work showing that growth hormone does not affect serum insulin like growth factor 1 concentrations in the absence of insulin.43 Growth hormone and insulin act synergistically in generating insulin like growth factor 1.44 Indirectly, during puberty an increase in serum insulin concentrations occurs during the growth spurt,29 and the postoperative growth of children deficient in growth hormone with craniopharyngiomas can be explained by increased insulin secretion.45 Diabetic children need an increased insulin dose during the growth spurt in puberty.
Roughly 44% of the children developed antibodies to somatrem; experience with patients with hypopituitarism produced similar results447; this suggests that the development of antibodies to growth hormone cannot be ascribed simply to patients being immunologically naive to growth hormone. It cannot be ascribed to the development ofantibodies toE coli protein either as in this study there was no relation between the development of antibodies to somatrem and antibodies to E coli proteins. There was also no relation in this study between the dose of growth hormone administered and the development of antibodies. The binding capacity of these antibodies was low, and no growth retardation was observed. Experience with antibodies to pituitary human growth hormone has shown that a binding capacity >5 mg/l leads to inhibition of growth.48 Antibody development is perhaps advantageous to patients as growth hormone activity has been shown to be enhanced by antibody formation.49
Previous studies have defined normality on the basis of pharmacological tests of growth hormone secretion.4-9 Analysis of the growth records of these children has shown that most were not growing normally and could conceivably have had growth hormone "neurosecretory dysfunction"" or yielded false positive results to tests. Further problems in interpreting some of the studies arose as puberty supervened in several of the children. We defined normality by growth velocity as well as by pharmacological tests and 24 hour growth hormone profiles. The normal growth velocity makes the possibility of our patients producing bioinactive growth hormone extremely unlikely.
This study has shown that giving growth hormone to children growing along or parallel to the third height centile leads to an increase in growth velocity without an untoward advance in bone age so that actual height is improved. Apart from an increase in the fasting insulin concentration there was no other untoward effect of treatment, and the increase in fasting concentrations of insulin may be an important requirement for the full expression of the anabolic effect of growth hormone. The extent to which the stature of these children will be improved in the long term remains to be seen. Good evidence now exists that the irritable bowel syndrome is a much more diffuse gut disorder than was originally appreciated,' and we reported recently that among other symptoms women with the syndrome commonly suffer from dyspareunia.2 Relatively little attention has been paid to the problem of sexual dysfunction in patients with gastrointestinal disorders except in relation to pelvic or abdominal surgery. We undertook a more detailed evaluation of sexual function in women with the irritable bowel syndrome, using groups ofwomen with colonic inflammatory bowel disease and duodenal ulceration as controls.
Patients, methods, and results
Fifty consecutive women outpatients with the irritable bowel syndrome (abdominal pain, abdominal distension, and an abnormal bowel habit) were studied, with no refusals. Patients with painless diarrhoea were excluded. The control group consisted of 30 patients with active duodenal ulceration and 30 with active inflammatory bowel disease affecting the colon with no history of surgery.
Five patients with inflammatory bowel disease and six with duodenal ulceration had symptoms suggesting coexisting irritable bowel syndrome and were not included in the conLol group because we would not have been able to ascertain which disorder was contributing to any sexual problem reported.
Forty two, 27, and 25 of the patients with, respectively, the irritable bowel syndrome, inflammatory bowel disease, and duodenal ulceration were sexually active. The distribution of social class in the groups was similar, but the mean age of the patients with duodenal ulcers was higher by nine years. Subjects were intorviewed by a woman doctor (a trained psychiatrist) in their own homes. As part of a wider assessment of psychosocial state patients completed a self report questionnaire about sexual function in relation to their bowel disorder; only those with-a score indicating severe or very severe disturbance (4 or 5 on a five point scale) were considered positive for the purposes of this analysis. Psychiatric state was measured with the psychiatric assessment schedule, a score of 11 or more indicating possible psychiatric illness.3 Results were analysed with contingency tables (X2).
The table shows that the irritable bowel syndrome was associated with a profound impairment of sexual function, with 83% of patients reporting problems compared with 300/o of women with inflammatory bowel disease and 16% of those with duodenal ulcers. When patients with psychiatric disorder were excluded from the analysis the same significant trend emerged, with 77%, 290/o, and 14%, respectively, of women showing sexual dysfunction.
Comment
This study showed that sexual dysfunction is common in women with the irritable bowel syndrome. The presence of abdominal symptoms cannot be the sole explanation as the controls were specifically chosen because they had abdominal disease. In addition, the explanation cannot simply be the presence of psychopathology4 because when women with psychiatric Number(%) ofsexually active women with the irritable bowel syndrome, inflammatory bowel disease, and duodenal ulceration with sexual dysfunction, and its relative significance 
